The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Open accessThe DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While most HDACi tend to employ a hydroxamic acid as a ZBG, class I HDACs (particularly HDACs 1–3) tend to be the only class of HDACs inhibited by 2-amino anilides as a ZBG (Figure 4A) [9–13].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
The impact of cellular metabolism on chromatin dynamics and epigenetics
Reid, M. A., Dai, Z., & Locasale, J. W. (2017) · Nature Cell Biology · doi:10.1038/ncb3629 · Cited by 515
Enhanced Histone Acetylation and Transcription: A Dynamic Perspective
Clayton, A. L., Hazzalin, C. A., & Mahadevan, L. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.017 · Cited by 473
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Cited by
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Smalley, J. P., Baker, I. M., Pytel, W. A., Lin, L., Bowman, K. J., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02179 · Cited by 85
Kaliman, P. (2018) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2018.11.010 · Cited by 97
Metadata
- Authors
- Cao, F., Zwinderman, M., & Dekker, F.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dekker, Frank
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-03-02
- Volume
- 23
- Issue
- 3
- Pages
- 551
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6017514
- OpenAlex
- W2791709427
- Cited by
- 66
- References
- 71
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 6 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 4
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- ERC (309782)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (723.012.005)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- HDAC3, HDAC3 inhibitors, selective inhibitors, epigenetic drug targets, cancer therapy, inflammation, neurodegenerative diseases
- MeSH terms
- Vorinostat, Panobinostat, Histone Deacetylase 3, Antineoplastic Agents, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Inflammation, Isoenzymes, Neoplasm Proteins, Neoplasms, Structure-Activity Relationship, Sulfonamides, Drug Design, Neurodegenerative Diseases, Epigenesis, Genetic, Depsipeptides, Histone Deacetylase Inhibitors, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. https://app.cochat.ai/papers/10.3390/molecules23030551
- The paper
- Cao, F., Zwinderman, M., & Dekker, F. (2018). The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. Molecules. https://doi.org/10.3390/molecules23030551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.